This invention relates to devices and methods for creating and maintaining a fluid conduit in a tissue wall. For example, some embodiments of the present invention may provide an alternative conduit between the left ventricle and the aorta to create a double-outlet left ventricle.
Construction of an alternative conduit between the left ventricle and the aorta (an apicoaortic conduit, or AAC) to create a double-outlet left ventricle (LV) has been successfully employed to treat a variety of complex congenital LV outflow obstruction (fibrous tunnel obstruction, aortic annular hypoplasia, tubular hypoplasia of the ascending aorta, and patients with diffuse septal thickening, severe LV hypertrophy and a small LV cavity) as well as adult-onset aortic stenosis in patients with complicating preoperative conditions (previous failed annular augmentation procedures, previous infection, previous CABG with patent anterior internal mammary artery grafts, and a porcelain ascending aorta).
However, the AAC insertion procedure has been poorly accepted, primarily because of early valve failures using first-generation bioprostheses as well as the success of direct LVOTO repair and aortic valve replacement. In the United States, despite an aging population, the unadjusted mortality for isolated aortic valve operations in 2001 remained under 4%. Further, the AAC insertion operation, with or without cardiopulmonary bypass, has not been as technically straightforward as direct aortic valve replacement. For most surgeons, AAC insertion is not a familiar operation and is of historical interest only.
Nonetheless, several studies have demonstrated that AAC insertion successfully lessens the LV-aortic pressure gradient, preserves or improves ventricular function and maintains normally distributed blood flow through the systemic and coronary circulation. While there have been several techniques described, the most commonly employed method is the lateral thoracotomy approach with placement of the AAC to the descending aorta. Other techniques include a median sternotomy approach with insertion of the distal limb of the AAC to the ascending aorta, to the transverse part of the aortic arch, or to the intra-abdominal supraceliac aorta.
In general, the thoracic aorta and the left ventricle apex are exposed through a left lateral thoracotomy, and a needle is passed through the apex and into the left ventricle. While the connector is still spaced apart from the apex, the sutures that will fix the connector to the apex are threaded through a cuff on the connector and through the apex in a matching pattern. The cuff is set back from the end of the connector by 1-2 centimeters to allow the end of the connector to extend through the heart muscle and into the left ventricle. Once the sutures are in place, a ventricular coring device is used to remove a core of ventricular muscle, and the pre-threaded sutures are then pulled to draw the connector into the opening until the cuff comes to rest: on the apex. The sutures are tied off, and additional sutures may be added. Either before or after this procedure, the opposite end of the connector is attached to a valved conduit which terminates at the aorta.
The current techniques and technology available to perform AAC insertion were originally designed to be performed on-pump; either with an arrested or fibrillating heart. While off-pump cases have been described, they can be technically difficult due to the shortcomings of presently available vascular conduits and systems for installing such conduits. For example, because existing conduits require the use of sutures to reliably secure the connector in place, it is often difficult for surgeons or other clinicians to insert such sutures reliably in active cardiac and/or vascular tissue.
This invention describes an improved system and method for the insertion of a vascular conduit (such as an AAC) that will significantly improve and simplify the in vivo insertion of a graft into the beating cardiac apex or other tissue walls (such as other areas of the heart including the anterior, lateral, posterior walls of the left or right ventricle, the left or right atrium, the aortic wall, ascending, transverse, or descending, or other blood vessel walls), such that vascular conduit insertions (including AAC procedures) may be rendered far more attractive to clinicians. Because vascular conduits and systems of the present invention may be used to create alternate outflow tracts in “off-pump” procedures, the embodiments of the present invention may effectively reduce and/or negate the detrimental effects of both cardio-pulmonary by-pass (CPB) and global cardiac ischemia. Additionally, because some conduit embodiments of the present invention (for AAC procedures, for example) may be inserted into a ventricular or atrial free wall or cardiac apex, the conduction system of the heart may be avoided, along with the native coronary arteries and grafts from previous surgical revascularization. In some embodiments of the present invention, wherein the system is used to implant an AAC, a small size valve (19 to 21 mm for typical adult body surface areas) is usually adequate; as the effective postoperative orifice is the sum of the native and prosthetic aortic valves. Further, the present invention provides vascular conduits that may be compatible with newer generation biologic valves, such that valved conduit failure is far less likely.
In one embodiment, the present invention provides a system for implanting a vascular conduit device (such as an AAC component). According to some embodiments, the system comprises a coring device for defining an aperture in a tissue wall (such as a cardiac free wall or apex and/or the aorta) having a first tissue surface and a second tissue surface. The coring device may define a lumen adapted to be capable of receiving a guide wire for directing the coring device to the first or second tissue surface, depending upon whether the approach is intra- or extra-vascular, respectively. The system may also comprise a conduit device for lining the aperture defined in the tissue wall and maintaining fluid communication between the first and second tissue surfaces of the tissue wall. The conduit device may be adapted to be capable of being advanced over the guide wire and/or the coring device so as to be guided to the aperture defined by the coring device. The conduit device may comprise, in some embodiments: a tube having proximal and distal ends, and inside and outside surfaces; a flexible flange disposed at or near the distal end, wherein the flexible flange is adapted to be capable of operably engaging the first tissue surface; and a securing ring adapted to fit over the tube and adapted to be capable of operably engaging the second tissue surface and cooperating with the flexible flange so as to secure the conduit device within the aperture.
According to some embodiments of the present invention, the system may also comprise a hemostatic device for selectively deploying so as to temporarily occlude the aperture (so as to prevent the passage of blood through the aperture and into an adjacent body cavity, for example). The hemostatic device may also be adapted to be capable of being advanced over the guide wire and/or within the lumen of the coring device such that the hemostatic device may be accurately guided to the site of the newly-formed aperture created by the coring device. The hemostatic device may comprise at least one of an “umbrella” occlusion device, a dilation balloon, and/or combinations of such devices. Furthermore, according to various system embodiments of the present invention, the coring device may comprise at least one of: a pulsed laser scalpel; a continuous wave laser scalpel; a mechanical coring device; a device employing ultrasonic energy (such as high-frequency focused ultra-sound); and/or combinations of such coring devices. Some embodiments of the present invention may also provide a specialized delivery device for enclosing the conduit device and selectively implanting the conduit device within the aperture. The delivery device may be operably engaged with an outer surface of the coring device and may comprise one or more retracting arms for dilating the aperture prior to and/or simultaneously with the implantation of the conduit device.
Some additional system embodiments of the present invention may also comprise a guiding catheter defining a guiding lumen for receiving and directing the coring device and the conduit device to the tissue wall via an endovascular pathway. Thus, according to various system embodiments of the present invention, the system may be used to implant the conduit device via an endovascular pathway such that the conduit may be implanted from inside the left ventricle and/or inside another blood vessel.
Other embodiments of the present invention provide a vascular conduit device for lining an aperture defined in a tissue wall (such as the cardiac wall, apex and/or a blood vessel wall) and maintaining fluid communication between a first tissue surface and a second tissue surface of the tissue wall. According to some embodiments, the vascular conduit device may comprise a tube having proximal and distal ends, and inside and outside surfaces, wherein the outside surface of the tube defines a plurality of ridges. The vascular conduit device may further comprise a flexible flange disposed at or near the distal end for operably engaging the first tissue surface and a securing ring adapted to fit over the tube for operably engaging the second tissue surface. The securing ring may also comprise at least one deformable pawl member for releasably engaging the plurality of ridges defined by the outer surface of the tube such that the securing ring cooperates with the flexible flange so as to secure the vascular conduit device within the aperture.
According to some embodiments, the flexible flange and/or securing ring may define complementary concave and/or convex profiles so as to conform more completely to the first and second tissue surfaces. Furthermore, the flexible flange may comprise a frusto-conical assembly such that the flange may be more easily inserted into the aperture. According to various other embodiments of the present invention, the outside surface of the tube may comprise threading on at least a portion of the outside surface of the tube and corresponding threading on an inside diameter of the securing ring such that the securing ring may be secured with respect to the flange and the tissue wall held there between.
According to some embodiments of the present invention, the flexible flange may be soft and thin enough to bend backwards so that it can be pushed through the aperture defined in the tissue wall, but rigid enough to flex back to its original position and hold its shape once it emerges along a first tissue surface of the tissue wall. The tube of the vascular conduit device may then be drawn back so that the flexible flange presses against the first tissue surface of the tissue wall. The securing ring may then be deployed over the body of the connector and against the second tissue surface of the tissue wall. Various vascular conduit device embodiments are described herein to secure the position of the second ring against a surface of the tissue wall such that no sutures may be required. Such embodiments may include, but are not limited to: the ridge and pawl mechanism described above, a threaded surfaces disposed on the tube and an inner surface of the securing ring, a biasing device for biasing the securing ring toward the flange; and/or combinations of such securing devices.
According to one embodiment for using the new system and/or vascular conduit device of the present invention, a needle is passed through a tissue wall (such as the wall of the cardiac apex) to provide access to the first tissue surface (defining the interior of the left ventricle, for example). A guide wire may then be inserted into the opening and, following dilation of the opening, an occlusion device may be threaded over the wire and into a cavity defined by the tissue wall and deployed. A coring device may then be threaded in-line over the guide wire such that a core of tissue may be removed to form an aperture in the tissue wall. While the occlusion device maintains hemostasis, the coring device may be removed and the vascular conduit device of the present invention may be mounted on a dilator and introduced over the guide wire and occlusion device catheter. As the vascular conduit device is introduced into the aperture, the flexible flange retracts. Furthermore, as discussed above, as the vascular conduit device enters the aperture, it may displace the occlusion device to allow the flange to resume its normal shape. As discussed above, the vascular conduit device may then be drawn tight against the first tissue wall such that the securing ring may be deployed over the body of the vascular conduit device to fit snugly against the second tissue surface. Once the connector is firmly in place, the occlusion device may be withdrawn and the vascular conduit device may be clamped shut while its free end is connected to a vascular graft or valved conduit that may terminate at another tissue wall (such as a blood vessel wall, for example).
Use of this new vascular conduit device, system, and method will significantly improve the ease and safety of vascular conduit insertion (such as the implantation of AAC devices). As persons of ordinary skill would readily appreciate, this method can also be, used in a minimally invasive, endoscopically assisted approach.
The invention will be better understood by reference to the Detailed Description of the Invention when taken together with the attached drawings, wherein:
The present inventions now will be described more fully hereinafter with reference to the accompanying drawings, in which some, but not all embodiments of the inventions are shown. Indeed, these inventions may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will satisfy applicable legal requirements. Like numbers refer to like elements throughout. The singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.
Although some embodiments of the invention described herein are directed to a vascular conduit device 100 and a system for implanting such a device to form an apico-aortic connector (AAC) between the cardiac apex and the aorta, it will be appreciated by one skilled in the art that the invention is not so limited. For example, aspects of the vascular conduit device 100 and systems of the present invention can also be used to establish and/or maintain conduits in a variety of tissue structures using minimally-invasive and/or invasive delivery techniques. Furthermore, while the embodiments of the invention described herein are directed to the thoracoscopic implantation of the vascular conduit device to form at least one vascular port for establishing an AAC, it should be understood that the system and/or vascular conduit device embodiments of the present invention may be used to establish valved and/or open conduits (including bypass conduits) to augment native blood vessels in order to treat a variety of vascular conditions including, but not limited to: aortic valvular disease, congestive heart failure, left ventricle outflow tract obstructions (LVOTO), peripheral arterial obstructions, small vessel obstructions, and/or other conditions. Furthermore, the vascular conduit device and system of the present invention may also be used to establish a port for inter-ventricular repairs such as, for example, valve repair and/or replacement or ablation procedures. Thus, the vascular conduit device 100 described in further detail below may also comprise a threaded fluid-tight cap, and/or a cap having at least one pawl member (for engaging corresponding ridges defined on an outer surface of the vascular conduit device 100) for selectively sealing the proximal end 7 of the vascular conduit device 100 such that the tube 1 may serve as a re-usable port for repairing and/or treating diseased portions of the cardiac anatomy. Furthermore, the vascular conduit device 100 and system embodiments of the present invention may also be used to implant a conduit and/or port for left ventricular assist devices.
Furthermore, (as shown generally in
As shown in
As shown generally in
As shown generally in
As discussed below, the flexible flange 13 and tube 1 of various embodiments of the vascular conduit device 100 may be altered so as to be compatible with various tissue walls 850. For example, the vascular conduit device 100 shown in
Therefore, as shown in
Tube 1 and flange 13 may be made-of any suitable biocompatible material. Alternatively, tube 1 and flange 13 may be coated with a biocompatible material. According to one exemplary embodiment, the tube 1 may comprise a first polymer material having a first hardness and the flange 13 may comprise a second polymer material having a second hardness, wherein the first hardness is greater than the second hardness. Thus, according to some such embodiments, the flange 13 may be easily deformable as it is inserted into the aperture 800 defined in the tissue wall 850, but the tube 1 may remain relatively rigid so as to maintain a path for fluid communication (see element 860,
According to some other embodiments, at least a portion of the outer surface 9 of tube 1 may be threaded. Threading 15 may extend the entire length of tube 1, or extend over only a portion thereof. According to one exemplary embodiment, threading 15 may be absent from a length of the distal end 5 of the tube 1 that is slightly less than the thickness of the tissue wall 850. This alternative embodiment may serve to prevent over-tightening of the vascular conduit device 100, which may, in some case lead to damage and/or rupture of portions of the tissue wall 850 near the aperture 800 defined therein. According to another embodiment, threading 15 may not extend all the way to the proximal end 7 such that the tube 1 (and the resulting vascular conduit device 100) may be used to provide a conduit through tissue walls having a variety of thicknesses.
External ring 17 (or securing ring 17) may be provided with an inner diameter 18 and an outer diameter 19. Inner diameter 18 may further define threads 23 to correspond to the threading 15 on the outer surface 9 of tube 1. The outer diameter 19 of external ring 17 may have any shape suitable to the designer, including circular or hexagonal. According to one embodiment of the invention, external ring 17 may be adapted to be engaged by a tightening device (not shown) for tightening external ring 17 on tube 1. As discussed above with respect to the tube 1, the external ring 17 may be made of any suitable biocompatible material. Alternatively, external ring 17 may be coated with a biocompatible material.
For embodiments wherein the tube defines threading 15 and wherein the complementary external ring 17 defines threads 23, the tightening device may comprise a specialized wrench device for rotating the external ring 17 relative to the tube 1. Furthermore, in other embodiments (such as those shown generally in
According to the embodiment shown in
According to some embodiments, release device 37 may also be provided to releasably hold external ring 17 and biasing device 27 in pre-deployment configuration, with biasing device 27 in compression, until such a time as the flange 13 has been placed in the interior of a cavity defined by the tissue wall 850 (such as the interior of the ventricle) and the external ring 17 is ready to be deployed against the outer tissue surface 855 of the heart muscle (see generally
According to the embodiment shown in
In some additional embodiments, a portion of tube 1 may be threaded and the inside diameter of external ring 17 threaded to permit further tightening of external ring 17 on tube 1 after deployment of the external ring 17 following removal of the release device 37.
Some embodiments of the present invention, as shown generally in
As shown in
According to various embodiments of the system of the present invention, the coring device 830 may comprise at least one of: a pulsed laser scalpel; a continuous wave laser scalpel; a mechanical coring device (such as, for example, a rotoblator catheter or other mechanical and/or catheter-based mechanical cutting device); an ultrasonic coring device (such as high-frequency focused ultra-sound); and combinations thereof. For example, in one exemplary embodiment, the coring device 830 may comprise a pulsed excimer laser device having a light pulse duration that is less than the tissue wall's 850 time of thermal diffusion (defining how quickly the laser's imparted heat spreads to adjacent tissue) so as to provide a relatively “cool” cutting method (i.e. less than about 50 degrees C.). Furthermore, the pulsed laser may be provided with a relatively shallow cutting depth (i.e. less than about 50 μm) such that the coring device 830 may be precisely controlled. The use of a pulsed laser scalpel as the coring device 830 may thus result in minimal damage to tissue adjacent the targeted aperture 800 area, which may be especially advantageous in embodiments wherein the system is used to implant a vascular conduit device 100 in the ventricular apex, as the cardiac tissue of the left ventricle contains tissues that are vital for maintaining the electrical pacing of the heart.
Some system embodiments of the present invention (as shown generally in
Following the coring process, the vascular conduit device 100 (as described in its various embodiments above) may be advanced along the outer surface of the coring device 830 and into position within the aperture (as shown generally in
For example, as shown generally in
As described above (see
According to one exemplary embodiment, the system of the present invention (shown generally in
A ventricular coring device 830 may then be threaded in-line over the hemostatic device 820 and a core of ventricular muscle is removed from the tissue wall 850 of the apex in order to form an aperture 800. In addition to known coring techniques, an annular contact laser (and in some embodiments a “cool” cutting pulsed excimer laser, having elements arranged in a circular array 835) may be used to vaporize the tissue along the perimeter of the core. The cored tissue may then be removed according to known methods. According to a further alternative embodiment, a contact laser may be used to vaporize the entire area of the core, eliminating the need to remove cored tissue. In yet another embodiment, a mechanical coring device (such as a catheter-based rotoblator device) or an ultrasonic coring device, may be used to form the aperture 800. No matter the method of coring, once coring has been-completed, the coring device 830 may be removed while the occlusion device maintains hemostasis, and the vascular conduit device 100 of the present invention may be mounted on a dilator and-introduced over the guide wire 810 and hemostatic device 820. As the vascular conduit device 100 is introduced into the aperture 800 in the apex, the flexible flange 13 may deform and/or retract. As the vascular conduit device 100 enters the-left ventricle, it may displace the hemostatic device 820 to allow the flexible flange 13 to resume its normal shape. As discussed above the vascular conduit device 100 may then be drawn tight against the first tissue surface 853 of the wall 850 of the left ventricle. According to a first embodiment, external ring 17 is threaded onto the tube 1 and tightened until it is snug against the second tissue surface 855 of the ventricular apex.
According to it second embodiment, once the flexible flange 13 has been introduced into the ventricle and pulled back to engage the first tissue surface 853, release-device 37 is released, allowing biasing device 27 to force the external ring 17 against the second tissue surface 855 of the ventricular apex. According to a further aspect of this embodiment of the invention, threads on the inside diameter of external ring 17 may be made to engage threads on the outer surface of the tube 1 to further secure external ring 17 against the tissue wall 850 of the ventricular apex.
Once the vascular conduit device 100 is firmly in place (see generally
Many modifications and other embodiments of the inventions set forth herein will come to mind to one skilled in the art to which these inventions pertain having the benefit of the teachings presented in the foregoing descriptions and the associated drawings. Therefore, it is to be understood that the inventions are not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.
This application is a continuation-in-part of copending U.S. patent application Ser. No. 10/915,691, filed on Aug. 11, 2004, now abandoned, which is hereby incorporated herein in its entirety by reference.
Number | Name | Date | Kind |
---|---|---|---|
3512519 | Hall | May 1970 | A |
3540451 | Zeman | Nov 1970 | A |
3856021 | McIntosh | Dec 1974 | A |
4336819 | Nishihara | Jun 1982 | A |
4366819 | Kaster | Jan 1983 | A |
4769031 | McGough et al. | Sep 1988 | A |
4904264 | Scheunemann | Feb 1990 | A |
5098369 | Heilman et al. | Mar 1992 | A |
5129913 | Ruppert | Jul 1992 | A |
5139517 | Corral | Aug 1992 | A |
5158563 | Cosman | Oct 1992 | A |
5222980 | Gealow | Jun 1993 | A |
5256160 | Clement | Oct 1993 | A |
5291179 | Ooe et al. | Mar 1994 | A |
5447533 | Vachon et al. | Sep 1995 | A |
5456714 | Owen | Oct 1995 | A |
5577993 | Zhu et al. | Nov 1996 | A |
5582616 | Bolduc et al. | Dec 1996 | A |
5695504 | Gifford et al. | Dec 1997 | A |
5755697 | Jones et al. | May 1998 | A |
5782844 | Yoon et al. | Jul 1998 | A |
5810836 | Hussein et al. | Sep 1998 | A |
5810851 | Yoon | Sep 1998 | A |
5814005 | Barra et al. | Sep 1998 | A |
5824070 | Jarvik | Oct 1998 | A |
5824071 | Nelson et al. | Oct 1998 | A |
5827316 | Young et al. | Oct 1998 | A |
5843088 | Barra et al. | Dec 1998 | A |
5893369 | LeMole | Apr 1999 | A |
5910153 | Mayenberger | Jun 1999 | A |
5924424 | Stevens et al. | Jul 1999 | A |
5944730 | Nobles et al. | Aug 1999 | A |
5976174 | Ruiz | Nov 1999 | A |
5984956 | Tweden et al. | Nov 1999 | A |
5989278 | Mueller | Nov 1999 | A |
6001056 | Jassawalla et al. | Dec 1999 | A |
6007576 | McClellan | Dec 1999 | A |
6022324 | Skinner | Feb 2000 | A |
6022367 | Sherts | Feb 2000 | A |
6039748 | Savage et al. | Mar 2000 | A |
6066085 | Heilman et al. | May 2000 | A |
6079414 | Roth | Jun 2000 | A |
6080173 | Williamson, IV et al. | Jun 2000 | A |
6080176 | Young | Jun 2000 | A |
6146325 | Lewis et al. | Nov 2000 | A |
6241743 | Levin et al. | Jun 2001 | B1 |
6254564 | Wilk et al. | Jul 2001 | B1 |
6267732 | Heneveld et al. | Jul 2001 | B1 |
6273862 | Privitera et al. | Aug 2001 | B1 |
6290728 | Phelps et al. | Sep 2001 | B1 |
6346071 | Mussivand | Feb 2002 | B1 |
6390976 | Spence et al. | May 2002 | B1 |
6401720 | Stevens et al. | Jun 2002 | B1 |
6409739 | Nobles et al. | Jun 2002 | B1 |
6443957 | Addis | Sep 2002 | B1 |
6458140 | Akin et al. | Oct 2002 | B2 |
6537300 | Girton | Mar 2003 | B2 |
6551319 | Lieberman | Apr 2003 | B2 |
6551332 | Nguyen et al. | Apr 2003 | B1 |
6589277 | Fabiani et al. | Jul 2003 | B1 |
6607541 | Gardiner et al. | Aug 2003 | B1 |
6638237 | Guiles et al. | Oct 2003 | B1 |
6651670 | Rapacki et al. | Nov 2003 | B2 |
6669708 | Nissenbaum et al. | Dec 2003 | B1 |
6673043 | Landesberg | Jan 2004 | B1 |
6676678 | Gifford, III et al. | Jan 2004 | B2 |
6689147 | Koster, Jr. | Feb 2004 | B1 |
6695859 | Golden et al. | Feb 2004 | B1 |
6699256 | Logan et al. | Mar 2004 | B1 |
6705988 | Spence et al. | Mar 2004 | B2 |
6726648 | Kaplon et al. | Apr 2004 | B2 |
6732501 | Yu et al. | May 2004 | B2 |
6740101 | Houser et al. | May 2004 | B2 |
6776787 | Phung et al. | Aug 2004 | B2 |
6802806 | McCarthy et al. | Oct 2004 | B2 |
6808498 | Laroya et al. | Oct 2004 | B2 |
6824071 | McMichael | Nov 2004 | B1 |
6827683 | Otawara | Dec 2004 | B2 |
6863677 | Breznock | Mar 2005 | B2 |
6942672 | Heilman et al. | Sep 2005 | B2 |
6984241 | Lubbers et al. | Jan 2006 | B2 |
6994666 | Shannon et al. | Feb 2006 | B2 |
7018384 | Skakoon | Mar 2006 | B2 |
7033372 | Cahalan | Apr 2006 | B1 |
7048681 | Tsubouchi et al. | May 2006 | B2 |
7056286 | Ravenscroft et al. | Jun 2006 | B2 |
7077801 | Haverich | Jul 2006 | B2 |
7083631 | Houser et al. | Aug 2006 | B2 |
7182771 | Houser et al. | Feb 2007 | B1 |
7214234 | Rapacki et al. | May 2007 | B2 |
7232421 | Gambale et al. | Jun 2007 | B1 |
7258694 | Choi et al. | Aug 2007 | B1 |
7309343 | Vargas et al. | Dec 2007 | B2 |
7331956 | Hovda et al. | Feb 2008 | B2 |
7404792 | Spence et al. | Jul 2008 | B2 |
7510561 | Beane et al. | Mar 2009 | B2 |
7637919 | Ishikawa et al. | Dec 2009 | B2 |
7717844 | Cohn | May 2010 | B2 |
7744527 | Cohn | Jun 2010 | B2 |
7766811 | Haverich | Aug 2010 | B2 |
7799041 | Beane et al. | Sep 2010 | B2 |
7842068 | Ginn | Nov 2010 | B2 |
7846123 | Vassiliades et al. | Dec 2010 | B2 |
7846179 | Belef et al. | Dec 2010 | B2 |
7931581 | Cohn | Apr 2011 | B2 |
7942805 | Shambaugh, Jr. | May 2011 | B2 |
7993392 | Righini et al. | Aug 2011 | B2 |
8226670 | Beane et al. | Jul 2012 | B2 |
8430836 | Vassiliades et al. | Apr 2013 | B2 |
8556930 | Ellingwood | Oct 2013 | B2 |
8579790 | Jeffery et al. | Nov 2013 | B2 |
20010051809 | Houser et al. | Dec 2001 | A1 |
20020019623 | Altman et al. | Feb 2002 | A1 |
20020019643 | Gifford et al. | Feb 2002 | A1 |
20020032462 | Houser et al. | Mar 2002 | A1 |
20020038127 | Blatter et al. | Mar 2002 | A1 |
20020045846 | Kaplon et al. | Apr 2002 | A1 |
20020058958 | Walen | May 2002 | A1 |
20020095210 | Finnegan et al. | Jul 2002 | A1 |
20020099394 | Houser et al. | Jul 2002 | A1 |
20020116018 | Stevens et al. | Aug 2002 | A1 |
20020177865 | McIntosh | Nov 2002 | A1 |
20020193806 | Moenning et al. | Dec 2002 | A1 |
20030023255 | Miles et al. | Jan 2003 | A1 |
20030040765 | Breznock | Feb 2003 | A1 |
20030045834 | Wing et al. | Mar 2003 | A1 |
20030078592 | Heilman et al. | Apr 2003 | A1 |
20030130668 | Nieman et al. | Jul 2003 | A1 |
20030181843 | Bibber et al. | Sep 2003 | A1 |
20040002624 | Yu et al. | Jan 2004 | A1 |
20040050393 | Golden et al. | Mar 2004 | A1 |
20040068299 | Laske et al. | Apr 2004 | A1 |
20040077989 | Goode et al. | Apr 2004 | A1 |
20040092858 | Wilson et al. | May 2004 | A1 |
20040097973 | Loshakove et al. | May 2004 | A1 |
20040098011 | Vargas et al. | May 2004 | A1 |
20040133155 | Varner et al. | Jul 2004 | A1 |
20040153112 | Nissenbaum et al. | Aug 2004 | A1 |
20040162608 | Haverich | Aug 2004 | A1 |
20040167547 | Beane et al. | Aug 2004 | A1 |
20040171905 | Yu et al. | Sep 2004 | A1 |
20040186490 | Gifford et al. | Sep 2004 | A1 |
20040236170 | Kim | Nov 2004 | A1 |
20050033107 | Tsubouchi | Feb 2005 | A1 |
20050043781 | Foley | Feb 2005 | A1 |
20050075656 | Beaupre | Apr 2005 | A1 |
20050101982 | Ravenscroft et al. | May 2005 | A1 |
20050101983 | Loshakove et al. | May 2005 | A1 |
20050131451 | Kleshinski et al. | Jun 2005 | A1 |
20050137609 | Guiraudon | Jun 2005 | A1 |
20050149093 | Pokorney | Jul 2005 | A1 |
20050154411 | Breznock et al. | Jul 2005 | A1 |
20050171479 | Hruska et al. | Aug 2005 | A1 |
20050187568 | Klenk et al. | Aug 2005 | A1 |
20050192604 | Carson et al. | Sep 2005 | A1 |
20050209502 | Schmid et al. | Sep 2005 | A1 |
20050251187 | Beane et al. | Nov 2005 | A1 |
20060020326 | Bolduc et al. | Jan 2006 | A9 |
20060036313 | Vassiliades | Feb 2006 | A1 |
20060074484 | Huber | Apr 2006 | A1 |
20060089707 | Vassiliades et al. | Apr 2006 | A1 |
20060099716 | Tipler et al. | May 2006 | A1 |
20060142634 | Anstadt et al. | Jun 2006 | A1 |
20060161193 | Beane et al. | Jul 2006 | A1 |
20060167333 | Moore et al. | Jul 2006 | A1 |
20060241659 | Tulleken et al. | Oct 2006 | A1 |
20060259050 | De Winter | Nov 2006 | A1 |
20070055357 | Pokorney et al. | Mar 2007 | A1 |
20070066943 | Prasad et al. | Mar 2007 | A1 |
20070088375 | Beane et al. | Apr 2007 | A1 |
20070100363 | Dollar et al. | May 2007 | A1 |
20070106315 | Gregoric et al. | May 2007 | A1 |
20070106328 | Wardle et al. | May 2007 | A1 |
20070167968 | Pandey | Jul 2007 | A1 |
20070167969 | Pandey | Jul 2007 | A1 |
20070173879 | Pandey | Jul 2007 | A1 |
20070197856 | Gellman et al. | Aug 2007 | A1 |
20070265643 | Beane et al. | Nov 2007 | A1 |
20080004640 | Ellingwood | Jan 2008 | A1 |
20080009668 | Cohn | Jan 2008 | A1 |
20080009887 | Cohn | Jan 2008 | A1 |
20080009891 | Cohn | Jan 2008 | A1 |
20080039883 | Nohilly | Feb 2008 | A1 |
20080058846 | Vosough | Mar 2008 | A1 |
20080076959 | Farnan et al. | Mar 2008 | A1 |
20080161826 | Guiraudon | Jul 2008 | A1 |
20080177301 | Svensson | Jul 2008 | A1 |
20080255597 | Pravong et al. | Oct 2008 | A1 |
20090012552 | Pandey et al. | Jan 2009 | A1 |
20090082778 | Beane et al. | Mar 2009 | A1 |
20090112062 | Bakos | Apr 2009 | A1 |
20090204206 | Parquet et al. | Aug 2009 | A1 |
20100004739 | Vesely | Jan 2010 | A1 |
20100010500 | Beane et al. | Jan 2010 | A1 |
20100087907 | Lattouf | Apr 2010 | A1 |
20100161040 | Braido et al. | Jun 2010 | A1 |
20100168778 | Braido | Jul 2010 | A1 |
20110118833 | Reichenbach et al. | May 2011 | A1 |
20110144680 | Nguyen et al. | Jun 2011 | A1 |
20120089181 | Shanley et al. | Apr 2012 | A1 |
20130218169 | Vassiliades et al. | Aug 2013 | A1 |
20140039375 | Jimenez et al. | Feb 2014 | A1 |
20140194833 | Andrus | Jul 2014 | A1 |
Number | Date | Country |
---|---|---|
2526920 | Feb 2009 | CA |
1842354 | Oct 2006 | CN |
1 669 042 | Jun 2006 | EP |
1691884 | Mar 2011 | EP |
1628702 | May 2013 | EP |
1706168 | Nov 2013 | EP |
11500642 | Jan 1999 | JP |
2002518082 | Jun 2002 | JP |
2006518624 | Aug 2006 | JP |
2007510522 | Apr 2007 | JP |
9325148 | Dec 1993 | WO |
9625886 | Aug 1996 | WO |
WO 9713463 | Apr 1997 | WO |
9965409 | Dec 1999 | WO |
0000193 | Jan 2000 | WO |
WO 0015147 | Mar 2000 | WO |
WO 0015149 | Mar 2000 | WO |
0041759 | Jul 2000 | WO |
0074747 | Dec 2000 | WO |
03001980 | Jan 2003 | WO |
2004026147 | Apr 2004 | WO |
2004096059 | Nov 2004 | WO |
2005046783 | May 2005 | WO |
2006019755 | Feb 2006 | WO |
2006020651 | Feb 2006 | WO |
2006093970 | Sep 2006 | WO |
2007038109 | Apr 2007 | WO |
2007047212 | Apr 2007 | WO |
2007117612 | Oct 2007 | WO |
2008131453 | Oct 2008 | WO |
2008153872 | Dec 2008 | WO |
2009100198 | Aug 2009 | WO |
2012040233 | Mar 2012 | WO |
2012103546 | Aug 2012 | WO |
2012106422 | Aug 2012 | WO |
2013064529 | May 2013 | WO |
Entry |
---|
Guidant Heartstring; originally retrieved from <http://www.guidant.com/products>; presently retrieved from <http://web.archive.org/web/20031206212233/http://www.guidant.com/products/producttemplates/cs/heartstring.shtml> dated 2003. |
International Preliminary Report on Patentability for Application No. PCT/US2005/028291; dated Mar. 3, 2009. |
International Search Report and Written Opinion for Application No. PCT/US2005/028291; dated May 28, 2008. |
International Preliminary Report on Patentability for Application No. PCT/US2006/039435; dated Apr. 16, 2008. |
International Search Report and Written Opinion for Application No. PCT/ US2006/039435; dated Feb. 6, 2007. |
Number | Date | Country | |
---|---|---|---|
20060089707 A1 | Apr 2006 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10915691 | Aug 2004 | US |
Child | 11251100 | US |